MedTrace Logo

Stem Cell Heart Injections During Laser Revascularization Surgery for Treatment of Chronic Ischemic Heart Disease

NCT03043742 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2020-12-11

No results posted yet for this study

Summary

Assess the safety and effectiveness of stem cell application with regard to improvement in regional myocardial function in patients receiving Trans-Myocardial Laser Revascularization (TMR) and stem cells.

Conditions

  • Chronic Ischemic Heart Disease

Interventions

DRUG

Bone Marrow Derived Autologous CD133+ Selected Cell Product

Injection of bone marrow derived autologous CD133+ cell product into laser channels during Trans-Myocardial Revascularization

Sponsors & Collaborators

  • Michael Sekela

    lead OTHER

Principal Investigators

  • Michael Sekela, MD · University of Kentucky

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-12
Primary Completion
2020-11-12
Completion
2020-11-12

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03043742 on ClinicalTrials.gov